Guiding ATMPs to patients
Here you will find information on what is happening in Sweden in development of medicines based on genes, cells or tissue engineering, classified as Advanced Therapy Medicinal Products (ATMPs) in Europe. We welcome your collaboration towards accelerated and efficacious patient solutions.
What ATMPs are patients receiving? What ATMP manufacture facilities do we have? What specialist treatment clinics are there? Find out this and more on our ATMP map
Subscribe to our mailing list
Subscribe to receive our quarterly newsletter and updates on the next ATMP Sweden conference.
Follow us on LinkedIn!
Work with us!
Join our experts in the science and technology for GMP compliant clinical translation of ATMPs.
Join our experts in the knowledge, processes and competencies for getting ATMPs to patients.
Find world class facilities, collaborators and resources to drive your ATMP development in Sweden.
News
Competence centre in NK cell-based immunotherapies to be formed
2019-06-24
A centre for development of the next generation NK cell-based immunotherapies against cancer to be built from Karolinska Institutet.
Read more
External ATMP Newsletter Midsummer 2019
2019-06-24
Register for our finance events and AdBIOPRO bioreactor course
Read more
Sweden’s first GMP line registered in hPSCreg
2019-06-24
KARO1 is the first GMP hESC line produced at Vecura, there are more to come!
Read moreATMP success stories
Resources
Use our interactive map to find clinics, manufacture facilities and CAMP/Swelife-ATMP partners.
Use this guide to navigate development of your ATMP to Phase I!
What is the difference between a transplant and a cell based ATMP?
Mikael Wiberg and Anna Sandström discuss the potential and challenges for ATMPs (Swedish)
Events
Find courses, training, conferences and more!
Other collaborating national projects
VOG cell is responsible for ensuring Swedish GMP manfacturing facilities function at the highest level and are compliant with current regulations.
AdBIOPRO is developing Continuous Processing of emerging potent therapeutic products such as recombinant viral vector and cell Products.
This Group will be developing a long term strategy for the future of the ATMP field in Sweden. The Project will ensure that all necessary networks and stakeholders are involved.
See all ATMP relevant organisations here